B cell lymphoma
Conditions
Interventions
Case series:none
Sponsors
Sun Yat-Sen University Cancer Center
Eligibility
Sex/Gender
All
Age
16 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. patients diagnosed as CD20 (+) B-cell lymphoma and received rituximab; 2. patients who had not been treated with chemotherapy or radiotherapy before, or more than 3 years after the last treatment of rituximab; 3. Imaging at least one measurable lesion; 4. patients aged from 16 to 80 years; 5. life expectancy greater than 12 weeks; 6. adequate organ function, Bone marrow reserve: hemoglobin = 9.0 g/dL, white blood cell = 3000/µL, neutrophil absolute value = 1500/µL, platelet = 100000/µL; renal function (serum creatinine = 1.5 mg / dL, creatinine clearance = 50 mL/min); upper limit of liver function (normal value of total bilirubin = 2 times), The upper limit of the normal value of alanine aminotransferase = 3 times), the normal electrocardiogram, the myocardial ejection fraction = 50.
Exclusion criteria
Exclusion criteria: 1. all kinds of congenital or acquired immunodeficiency patients, such as: AIDSN Wiskott-Aldrich syndrome, hereditary ataxia-telangiectasia, liver/kidney transplantation patients who nedd long-term oral anti-rejection drugs and other immunodeficiency patients; 2. Secondary lymphoma developed after chemotherapy or radiotherapy for other malignant tumors; 3. Patients with active infections requiring systemic antibiotic or antiviral therapy; 4. Patients with decompensated heart failure, dilated cardiomyopathy, St segment depression coronary heart disease or experienced myocardial infarction in the last 6 months; 5. Patients with severe mental illness; lactation or pregnancy women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;adverse events; | — |
Countries
China
Contacts
Public ContactWang Xueding
Outcome results
None listed